BRIEF-Ligand enters into worldwide Omniab platform license agreement with Surface Oncology

* Ligand enters into worldwide Omniab® platform license agreement with Surface Oncology
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.